18F‐fluoro‐deoxyglucose positron emission tomography in assessment of myeloma‐related bone disease: A systematic review
- 1 September 2011
- Vol. 118 (8) , 1971-1981
Abstract
BACKGROUND: The goal of this study was to conduct a comparative analysis of whole body X‐ray (WBXR) and 18F‐fluoro‐deoxyglucose positron emission tomography (18FDG PET) in staging and response assessment of multiple myeloma.METHODS: We performed a systematic review of studies comparing 18FDG PET with WBXR and/or magnetic resonance imaging in terms of sensitivity for myeloma‐related bone disease at staging and during follow‐up.RESULTS: Eighteen studies involving 798 patients met the inclusion criteria. The mean Quality Assessment of Diagnostic Accuracy Studies (QUADAS) score, expressed as a percentage of the maximum score, was 61%. In 7 studies (n = 242 patients), concordance assessment between WBXR and 18FDG PET scan was possible, showing a higher sensitivity of the 18FDG PET in the detection of myeloma bone lesions in 6 studies. The only study reporting on the prognostic value of 18FDG PET at staging found that the number of FDG‐avid focal lesions was an independent prognostic parameter. In addition, the limited studies on response monitoring showed that normalization of 18FDG PET during treatment correlated with a superior clinical outcome.CONCLUSIONS: In general, 18FDG PET has a superior sensitivity for myeloma bone lesions compared with WBXR. Future studies have to validate the additive value of myeloma‐related bone disease detected on 18FDG PET–computed tomography (CT) in predicting outcome. Response monitoring with the use of 18FDG PET‐CT during treatment is promising, allowing more precise prediction of prognosis compared with the standard response monitoring. In view of the expanding treatment options for multiple myeloma, this may provide important information for treatment decisions in the future. Cancer 2012. © 2011 American Cancer Society.Keywords
This publication has 25 references indexed in Scilit:
- F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myelomaBlood, 2009
- International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple MyelomaLeukemia, 2009
- A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myelomaHaematologica, 2007
- Comparison of imaging with FDG PET/CT with other imaging modalities in myelomaSkeletal Radiology, 2006
- Value of FDG PET in the Assessment of Patients with Multiple MyelomaAmerican Journal of Roentgenology, 2005
- Development and validation of methods for assessing the quality of diagnostic accuracy studiesHealth Technology Assessment, 2004
- How to perform a comprehensive search for FDG-PET literatureEuropean Journal of Nuclear Medicine and Molecular Imaging, 2000
- PET in oncology: Will it replace the other modalities?Seminars in Nuclear Medicine, 1997
- Fluorination with molecular fluorine. A convenient synthesis of 2-deoxy-2-fluoro-D-glucoseThe Journal of Organic Chemistry, 1977
- A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survivalCancer, 1975